Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

June 2, 2024

https://www.globenewswire.com/news-release/2024/06/02/2891849/24180/en/Celldex-Therapeutics-Presents-Data-Demonstrating-Profound-Improvements-in-Angioedema-in-Barzolvolimab-Phase-2-Study-in-Chronic-Spontaneous-Urticaria-at-EAACI-2024.html

– Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups –
– Sustained activity with rapid onset within 2 weeks –
– Data further support barzolvolimab clinical benefit to patients with CSU –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.